Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical case of LANDMARK◊ Total Knee System

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and has completed the first surgical case with LANDMARK Total Knee System, a next-generation knee replacement solution designed to replicate healthy knee anatomy and the knee’s natural motion and support a more personalized approach to total knee arthroplasty.

As expectations for total knee arthroplasty continue to evolve, surgeons and patients are seeking the most advanced and tailored solutions when they choose a knee replacement solution. The LANDMARK Knee meets those goals through an anatomy-driven implant that was designed to leverage the full capabilities of CORI◊ KNEE Handheld Robotics Arthroplasty.1 The compact footprint and mobility of Handheld Robotics is optimized for use across both hospital and ambulatory surgery center (ASC) environments.

Key features of the LANDMARK Knee include:

• Designed to replicate healthy knee anatomy and restore the natural motion and A/P position with less compromise2-6*

• Smooth, flat trochlear groove entry point to promote more natural patella tracking 2,7,8*

• Fully 3D-printed femoral component utilizing CONCELOC◊ Technology3

“It is truly a landmark moment for Orthopaedics at Smith+Nephew. The future of knee replacement is increasingly personalized, and surgeons need technologies that help them deliver individualized care with confidence and efficiency,” said Nate Folkert, President, Smith+Nephew Orthopaedics. “Together, the natural design of LANDMARK Knee paired with CORI KNEE Handheld Robotics Arthroplasty provides a powerful solution to address the evolving needs of orthopaedic surgery."

The first LANDMARK Knee surgical case was completed this week by Dr. Steven MacDonald, Professor of Orthopaedic Surgery, Western University and London Health Sciences Centre in London, Ontario, who is one of the surgeons who helped with the design and development of this innovative implant system. “Knee replacement surgery has changed so much in recent years driven by the momentum of personalized medicine and an influx of innovative approaches,” explained Dr. MacDonald. "Whether achieved via the state-of-the-art new LANDMARK instrumentation system or in combination with the planning and balancing capabilities of the CORI KNEE Handheld Robotics Arthroplasty, the LANDMARK Knee provides us the flexibility to make patient-specific decisions while maintaining procedural efficiency. It is the perfect fit for surgeons looking to align with the principles of personalized care as the LANDMARK Knee was designed to meet the needs of surgeons and patients today and tomorrow."

Dr. Steven Haas, Chief of the Knee Service at Hospital for Special Surgery (HSS) in New York, was also a surgeon developer of the LANDMARK Knee. "The LANDMARK Knee was designed to address one of the biggest challenges in total knee arthroplasty, which is restoring anatomy without forcing unnecessary compromise," Dr. Haas said. "Its anatomic design helps accommodate the patient's natural anatomy while supporting personalized alignment and patellofemoral function.”

The LANDMARK Knee will be commercially introduced through a phased launch focused on early customer adoption, with broader availability across markets expected throughout 2027. Smith+Nephew will be unveiling its new knee system to HCP attendees during the American Association of Hip & Knee Surgeons (AAHKS) Annual Meeting in Dallas November 5-8. Stop by booth number 621 to see the new LANDMARK Knee in action.

To learn more, visit our LANDMARK Knee website: https://www.smith-nephew.com/en-us/health-care-professionals/products/orthopaedics/landmark-tks. 

Media Enquiries

Gina Kamler

+1 (901) 262-9070

gina.kamler@smith-nephew.com

 * Compared to conventional TKA designs

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of

$6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on

LinkedIn, Instagram or Facebook.

Forward-looking statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.